These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25557156)

  • 1. Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease.
    Matera MG; Cardaci V; Cazzola M; Rogliani P
    Expert Opin Drug Saf; 2015 Apr; 14(4):533-41. PubMed ID: 25557156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhaled corticosteroids for chronic obstructive pulmonary disease.
    Cazzola M; Rogliani P; Novelli L; Matera MG
    Expert Opin Pharmacother; 2013 Dec; 14(18):2489-99. PubMed ID: 24138334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How and when to use inhaled corticosteroids in chronic obstructive pulmonary disease?
    Antón E
    Expert Rev Respir Med; 2013 Apr; 7(2 Suppl):25-32. PubMed ID: 23551021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing the safety of inhaled corticosteroids in COPD and the risk of pneumonia.
    Liapikou A; Toumbis M; Torres A
    Expert Opin Drug Saf; 2015 Aug; 14(8):1237-47. PubMed ID: 26113207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS.
    Latorre M; Novelli F; Vagaggini B; Braido F; Papi A; Sanduzzi A; Santus P; Scichilone N; Paggiaro P
    Pulm Pharmacol Ther; 2015 Feb; 30():44-50. PubMed ID: 25445928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic effects of inhaled corticosteroids.
    Ernst P; Suissa S
    Curr Opin Pulm Med; 2012 Jan; 18(1):85-9. PubMed ID: 22112998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled corticosteroids and the increased risk of pneumonia: what's new? A 2015 updated review.
    Iannella H; Luna C; Waterer G
    Ther Adv Respir Dis; 2016 Jun; 10(3):235-55. PubMed ID: 26893311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
    Sobieraj DM; White CM; Coleman CI
    Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhaled corticosteroids and the increased risk of pneumonia.
    Marzoratti L; Iannella HA; Waterer GW
    Ther Adv Respir Dis; 2013 Aug; 7(4):225-34. PubMed ID: 23445751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety considerations of inhaled corticosteroids in the elderly.
    Battaglia S; Cardillo I; Lavorini F; Spatafora M; Scichilone N
    Drugs Aging; 2014 Nov; 31(11):787-96. PubMed ID: 25212953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and associated factors of oropharyngeal side effects in users of inhaled corticosteroids in a real-life setting.
    Molimard M; Le Gros V; Robinson P; Bourdeix I
    J Aerosol Med Pulm Drug Deliv; 2010 Apr; 23(2):91-5. PubMed ID: 19778267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risk and outcomes of pneumonia in patients on inhaled corticosteroids.
    Sibila O; Soto-Gomez N; Restrepo MI
    Pulm Pharmacol Ther; 2015 Jun; 32():130-6. PubMed ID: 25956073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Inhaled corticosteroids in COPD and the risk of pneumonia].
    Niţu M; Medregoniu D; Olteanu M; Golli A; Olteanu M; Măceşeanu A; Medregoniu R
    Pneumologia; 2010; 59(2):74-6. PubMed ID: 20695361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erratum to: Safety Considerations of Inhaled Corticosteroids in the Elderly.
    Battaglia S; Cardillo I; Lavorini F; Spatafora M; Scichilone N
    Drugs Aging; 2015 Dec; 32(12):1067-76. PubMed ID: 26578157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic assessment of early initiation of inhaled corticosteroids in chronic obstructive pulmonary disease using propensity score matching.
    Akazawa M; Biddle AK; Stearns SC
    Clin Ther; 2008; 30 Spec No():1003-16. PubMed ID: 18640475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of corticosteroids in chronic obstructive pulmonary disease.
    Calverley PM
    Semin Respir Crit Care Med; 2005 Apr; 26(2):235-45. PubMed ID: 16088440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease.
    Matera MG; Capuano A; Cazzola M
    Expert Rev Respir Med; 2015 Feb; 9(1):5-12. PubMed ID: 25482512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale.
    Magnussen H; Watz H; Kirsten A; Decramer M; Dahl R; Calverley PM; Towse L; Finnigan H; Tetzlaff K; Disse B
    Respir Med; 2014 Apr; 108(4):593-9. PubMed ID: 24477080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation of Inhaled Corticosteroids in COPD and the Risk Reduction of Pneumonia.
    Suissa S; Coulombe J; Ernst P
    Chest; 2015 Nov; 148(5):1177-1183. PubMed ID: 26110239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association of inhaled corticosteroid use with serum glucose concentration in a large cohort.
    Slatore CG; Bryson CL; Au DH
    Am J Med; 2009 May; 122(5):472-8. PubMed ID: 19375557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.